In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically

Jrhau Lung, Kuan Liang Chen, Chien Hui Hung, Chih Cheng Chen, Ming Szu Hung, Yu Ching Lin, Ching Yuan Wu, Kuan Der Lee, Neng Yao Shih, Ying Huang Tsai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Unlimited growth of cancer cells requires an extensive nutrient supply. To meet this demand, cancer cells drastically upregulate glucose uptake and metabolism compared to normal cells. This difference has made the blocking of glycolysis a fascinating strategy to treat this malignant disease. α-enolase is not only one of the most upregulated glycolytic enzymes in cancer cells, but also associates with many cellular processes or conditions important to cancer cell survival, such as cell migration, invasion, and hypoxia. Targeting α-enolase could simultaneously disturb cancer cells in multiple ways and, therefore, is a good target for anticancer drug development. In the current study, more than 22 million chemical structures meeting the criteria of Lipinski’s rule of five from the ZINC database were docked to α-enolase by virtual screening. Twenty-four chemical structures with docking scores better than that of the enolase substrate, 2-phosphoglycerate, were further screened by the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties prediction. Four of them were classified as non-mutagenic, non-carcinogenic, and capable of oral administration where they showed steady interactions to α-enolase that were comparable, even superior, to the currently available inhibitors in molecular dynamics (MD) simulation. These compounds may be considered promising leads for further development of the α-enolase inhibitors and could help fight cancer metabolically.

Original languageEnglish
Pages (from-to)3281-3290
Number of pages10
JournalDrug Design, Development and Therapy
Volume11
DOIs
Publication statusPublished - Nov 16 2017

Fingerprint

Forensic Anthropology
Phosphopyruvate Hydratase
Computer Simulation
Growth
Neoplasms
Cell Hypoxia
Glycolysis
Molecular Dynamics Simulation
Cell Movement
Oral Administration
Cell Survival
Up-Regulation
Databases
Glucose
Food
Enzymes
Pharmaceutical Preparations

Keywords

  • Glycolysis
  • Metabolism
  • Molecular dynamics simulation
  • Virtual screening
  • α-enolase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Lung, J., Chen, K. L., Hung, C. H., Chen, C. C., Hung, M. S., Lin, Y. C., ... Tsai, Y. H. (2017). In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically. Drug Design, Development and Therapy, 11, 3281-3290. https://doi.org/10.2147/DDDT.S149214

In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically. / Lung, Jrhau; Chen, Kuan Liang; Hung, Chien Hui; Chen, Chih Cheng; Hung, Ming Szu; Lin, Yu Ching; Wu, Ching Yuan; Lee, Kuan Der; Shih, Neng Yao; Tsai, Ying Huang.

In: Drug Design, Development and Therapy, Vol. 11, 16.11.2017, p. 3281-3290.

Research output: Contribution to journalArticle

Lung, Jrhau ; Chen, Kuan Liang ; Hung, Chien Hui ; Chen, Chih Cheng ; Hung, Ming Szu ; Lin, Yu Ching ; Wu, Ching Yuan ; Lee, Kuan Der ; Shih, Neng Yao ; Tsai, Ying Huang. / In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically. In: Drug Design, Development and Therapy. 2017 ; Vol. 11. pp. 3281-3290.
@article{5dac7cb3590f48829eaeeb288f509fab,
title = "In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically",
abstract = "Unlimited growth of cancer cells requires an extensive nutrient supply. To meet this demand, cancer cells drastically upregulate glucose uptake and metabolism compared to normal cells. This difference has made the blocking of glycolysis a fascinating strategy to treat this malignant disease. α-enolase is not only one of the most upregulated glycolytic enzymes in cancer cells, but also associates with many cellular processes or conditions important to cancer cell survival, such as cell migration, invasion, and hypoxia. Targeting α-enolase could simultaneously disturb cancer cells in multiple ways and, therefore, is a good target for anticancer drug development. In the current study, more than 22 million chemical structures meeting the criteria of Lipinski’s rule of five from the ZINC database were docked to α-enolase by virtual screening. Twenty-four chemical structures with docking scores better than that of the enolase substrate, 2-phosphoglycerate, were further screened by the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties prediction. Four of them were classified as non-mutagenic, non-carcinogenic, and capable of oral administration where they showed steady interactions to α-enolase that were comparable, even superior, to the currently available inhibitors in molecular dynamics (MD) simulation. These compounds may be considered promising leads for further development of the α-enolase inhibitors and could help fight cancer metabolically.",
keywords = "Glycolysis, Metabolism, Molecular dynamics simulation, Virtual screening, α-enolase inhibitor",
author = "Jrhau Lung and Chen, {Kuan Liang} and Hung, {Chien Hui} and Chen, {Chih Cheng} and Hung, {Ming Szu} and Lin, {Yu Ching} and Wu, {Ching Yuan} and Lee, {Kuan Der} and Shih, {Neng Yao} and Tsai, {Ying Huang}",
year = "2017",
month = "11",
day = "16",
doi = "10.2147/DDDT.S149214",
language = "English",
volume = "11",
pages = "3281--3290",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically

AU - Lung, Jrhau

AU - Chen, Kuan Liang

AU - Hung, Chien Hui

AU - Chen, Chih Cheng

AU - Hung, Ming Szu

AU - Lin, Yu Ching

AU - Wu, Ching Yuan

AU - Lee, Kuan Der

AU - Shih, Neng Yao

AU - Tsai, Ying Huang

PY - 2017/11/16

Y1 - 2017/11/16

N2 - Unlimited growth of cancer cells requires an extensive nutrient supply. To meet this demand, cancer cells drastically upregulate glucose uptake and metabolism compared to normal cells. This difference has made the blocking of glycolysis a fascinating strategy to treat this malignant disease. α-enolase is not only one of the most upregulated glycolytic enzymes in cancer cells, but also associates with many cellular processes or conditions important to cancer cell survival, such as cell migration, invasion, and hypoxia. Targeting α-enolase could simultaneously disturb cancer cells in multiple ways and, therefore, is a good target for anticancer drug development. In the current study, more than 22 million chemical structures meeting the criteria of Lipinski’s rule of five from the ZINC database were docked to α-enolase by virtual screening. Twenty-four chemical structures with docking scores better than that of the enolase substrate, 2-phosphoglycerate, were further screened by the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties prediction. Four of them were classified as non-mutagenic, non-carcinogenic, and capable of oral administration where they showed steady interactions to α-enolase that were comparable, even superior, to the currently available inhibitors in molecular dynamics (MD) simulation. These compounds may be considered promising leads for further development of the α-enolase inhibitors and could help fight cancer metabolically.

AB - Unlimited growth of cancer cells requires an extensive nutrient supply. To meet this demand, cancer cells drastically upregulate glucose uptake and metabolism compared to normal cells. This difference has made the blocking of glycolysis a fascinating strategy to treat this malignant disease. α-enolase is not only one of the most upregulated glycolytic enzymes in cancer cells, but also associates with many cellular processes or conditions important to cancer cell survival, such as cell migration, invasion, and hypoxia. Targeting α-enolase could simultaneously disturb cancer cells in multiple ways and, therefore, is a good target for anticancer drug development. In the current study, more than 22 million chemical structures meeting the criteria of Lipinski’s rule of five from the ZINC database were docked to α-enolase by virtual screening. Twenty-four chemical structures with docking scores better than that of the enolase substrate, 2-phosphoglycerate, were further screened by the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties prediction. Four of them were classified as non-mutagenic, non-carcinogenic, and capable of oral administration where they showed steady interactions to α-enolase that were comparable, even superior, to the currently available inhibitors in molecular dynamics (MD) simulation. These compounds may be considered promising leads for further development of the α-enolase inhibitors and could help fight cancer metabolically.

KW - Glycolysis

KW - Metabolism

KW - Molecular dynamics simulation

KW - Virtual screening

KW - α-enolase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85035193635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035193635&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S149214

DO - 10.2147/DDDT.S149214

M3 - Article

AN - SCOPUS:85035193635

VL - 11

SP - 3281

EP - 3290

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -